NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/moonlake-lawsuit-s ...

Core Viewpoint - A class action securities lawsuit has been filed against Firefly Aerospace Inc. due to alleged securities fraud affecting investors who purchased shares during the company's IPO and subsequent period [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals and entities that acquired Firefly common stock related to the IPO on August 7, 2025, and those who purchased Firefly securities between August 7, 2025, and September 29, 2025 [2]. Case Details - The complaint alleges that the defendants made false statements and concealed critical information, including: - Overstated demand and growth prospects for Firefly's Spacecraft Solutions offerings [3] - Overstated operational readiness and commercial viability of the Alpha rocket program [3] - The revelation of these issues would likely have a material negative impact on the company [3] - Offering documents and public statements were materially false and misleading [3] Next Steps - Investors who suffered losses during the relevant timeframe have until January 12, 2026, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. No Cost to Participants - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [4]. Why Levi & Korsinsky - The firm has a strong track record in securing significant recoveries for shareholders and is recognized as one of the top securities litigation firms in the United States [5].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance and operational improvements [2]. - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint highlights significant manufacturing deficiencies in the facility dedicated to the infant formula business [2]. - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were reportedly overstated [2]. - The positive statements made by the defendants regarding the Company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until January 16, 2026, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - A class action securities lawsuit has been filed against Marex Group plc, alleging securities fraud that affected investors between May 16, 2024, and August 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Marex Group plc made false statements and concealed information regarding the improper inflation of cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these actions, the positive statements made by the defendants about the Company's business and prospects were materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until December 8, 2025, to request to be appointed as lead plaintiff in the case [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against DexCom, Inc. alleging securities fraud that affected investors between January 8, 2024, and September 17, 2025 [1] Group 1: Allegations of the Lawsuit - The lawsuit claims that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, without FDA approval [2] - It is alleged that these design changes made the G6 and G7 less reliable, posing a material health risk to users who depend on these devices for accurate glucose readings [2] - The complaint asserts that the enhancements to the G7 and its reliability, accuracy, and functionality were overstated by the defendants [2] - Defendants allegedly downplayed the severity of the issues and health risks associated with the altered G7 devices [2] - The lawsuit indicates that these actions exposed DexCom to increased regulatory scrutiny and potential legal, reputational, and financial harm [2] - As a result, the public statements made by the defendants were claimed to be materially false and misleading [2] Group 2: Next Steps for Affected Investors - Investors who suffered losses in DexCom during the specified timeframe have until December 26, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - A class action securities lawsuit has been filed against CarMax, Inc. alleging securities fraud that affected investors between June 20, 2025, and November 5, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding CarMax's growth prospects, suggesting that earlier growth was a temporary benefit due to speculation about tariffs [2]. - It is alleged that the statements made by defendants about CarMax's business and operations were materially false and misleading, lacking a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 2, 2026, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in StubHub Holdings, Inc. ("StubHub Holdings, Inc." or the "Company") (NYSE: STUB) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of StubHub Holdings, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons and entities that purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registration ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd." or the "Company") (NASDAQ: TLX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Telix Pharmaceuticals Ltd. investors who were adversely affected by alleged securities fraud between February 21, 2025 and August 28, 2025. Follow the link below to get more information and be contacted by a member of our team:https:// ...

WHAT'S NEXT? If you suffered a loss in Inspire Medical Systems, Inc. during the relevant time frame, you have until January 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team ...

NEW YORK, Dec. 5, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in James Hardie Industries plc. ("James Hardie Industries plc." or the "Company") (NYSE: JHX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of James Hardie Industries plc. investors who were adversely affected by alleged securities fraud between May 20, 2025 and August 18, 2025. Follow the link below to get more information and be contacted by a member of our team:https://z ...